
Summit Therapeutics (SMMT) Stock Forecast & Price Target
Summit Therapeutics (SMMT) Analyst Ratings
Bulls say
Summit Therapeutics Inc is poised for significant growth, driven by the favorable clinical performance of its product candidates, particularly ridinilazole for Clostridiodes difficile infection. The encouraging results from the HARMONi trial, with 65% of patients already showing a progression-free survival (PFS) benefit, enhance confidence in successful outcomes for upcoming data readouts in 2025. Furthermore, predictions of substantial peak annual sales for its oncology treatments reveal the potential for market competitiveness, positioning Summit favorably in the biopharmaceutical landscape.
Bears say
Summit Therapeutics's outlook remains negative primarily due to significant regulatory and clinical risks associated with its product candidates. The potential for marginal clinical efficacy or the emergence of new safety signals in ongoing trials lowers the probability of success for its treatments, which may lead to price declines despite meeting investor expectations. Additionally, the lack of differentiated clinical data and concerns about competition, coupled with a projected net loss per share and potential dilution risks, further exacerbate the concerns surrounding the company’s financial stability.
This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Summit Therapeutics (SMMT) Analyst Forecast & Price Prediction
Start investing in Summit Therapeutics (SMMT)
Order type
Buy in
Order amount
Est. shares
0 shares